The India Portfolio
Dr Reddy’s India takes forward our mission of Good Health Can’t Wait, through a diverse portfolio of 300+ branded generic products. We are driving advances in vital therapeutic domains: gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
The India business rests on solid pillars: building strong brands, driving successful product launches, dedicated R&D, and proactive thought leadership to raise therapy awareness nationwide. Our rural access initiative Vistara has reached 125,000 healthcare professionals, positively impacting 50 million patients in 10,000 Indian towns. Strengthening our chronic therapy portfolio is our focus as we tackle pressing healthcare challenges head-on.
Our brands
Some of our brands that have stayed at the top of the Indian pharmaceutical market, and have become well-known names. Sixteen of our brands consistently achieved revenues surpassing Rs. 100 crore (August 2022)
Pioneering Therapies
Our India operation revolves around key therapies, housing a treasure trove of 300+ brands, and led by an empowered team of nearly 9000. Our new product launches have surged, with a remarkable 41 products introduced in FY 2022 alone. We've secured a top 5 rank in oncology, allergy, and gastrointestinal diseases, and a spot in the top 10 across several other therapy areas.
Nutraceuticals
It's not just about products – it's about reaching further, touching lives through nutrition, wellness, and solutions tailored to unmet patient needs. Since 2019, our venture into nutraceuticals has thrived, embracing science-based solutions across diverse sectors. Our path begins with understanding, leading to evidence-based breakthroughs. A prime example is Celevida, born from insights into diabetes nutrition.
Our nutraceutical offerings are driven by our specialised unit Vivera, with a dedicated sales force that champions nutrition for good health. Bolstered by specialists in fresh nutrition, the team has developed a range of offerings including Celevida DLS, Celevida Maxx, Celevida Liv, and more. The aim: To make evidence-based products accessible, to cater to specific and unmet needs such as diabetic nutrition and hospital nutrition.